Baculovirus Surface Display of EV71 Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional EV71 vaccines are challenging to produce due to the virulent nature of the virus, requiring biosafety level conditions and significant changes in manufacturing procedures, which can delay vaccine production during outbreaks, and existing vaccines have shown limited efficacy in controlling epidemics.
Innovation Solution
Development of an expression cassette comprising an ie1 promoter from white spot syndrome virus, a nucleic acid sequence encoding an N-terminal gp64 signal peptide, an antigenic peptide, and a gp64 cytoplasmic region, integrated into an expression vector and host cell, allowing for the surface display of antigenic peptides on baculoviruses, which can be used as a vaccine to stimulate an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional EV71 vaccines are produced using inactivated viruses, then vaccine production can be achieved, but the process requires biosafety level conditions and significant manufacturing changes that delay production
Solution Approach 1:
The invention extracts only the essential antigenic components (capsid proteins VP1, VP2, VP3) from the complete EV71 virus, eliminating the need to handle the entire virulent virus. This extraction of key immunogenic elements allows production without biosafety level containment while maintaining vaccine efficacy.
Solution Approach 2:
Instead of using the actual EV71 virus, the invention creates a recombinant baculovirus copy that expresses EV71 antigenic proteins. This viral vector system replicates the immunogenic properties of EV71 without requiring the pathogenic virus itself, enabling safer and faster production.
2Ease of manufacture
If conventional inactivated virus vaccines are used, then vaccine production is possible, but the virulent nature of the virus requires biosafety level conditions and significant manufacturing procedure changes
Solution Approach 1:
The invention uses a recombinant baculovirus vector system that copies only the necessary antigenic sequences from EV71, eliminating the need for complex biosafety infrastructure. The baculovirus expression system provides a standardized, simpler manufacturing platform that doesn't require handling of virulent EV71 virus.
Solution Approach 2:
The baculovirus vector serves as an intermediary carrier that delivers EV71 antigenic genes to host cells for protein expression. This mediator system separates the immunogenic function from the pathogenic function, allowing production without direct manipulation of virulent EV71 virus and reducing manufacturing complexity.
3Reliability
If existing EV71 vaccines are administered, then some immune response is achieved, but the neutralization titers are limited and epidemic control is insufficient
Solution Approach 1:
The invention focuses on displaying multiple antigenic determinants (VP1, VP2, VP3 capsid proteins) on the surface of baculovirus particles, creating a concentrated array of immunogenic epitopes. This localized concentration of antigenic quality enhances immune recognition and neutralization antibody production compared to conventional vaccines.
Solution Approach 2:
The vaccine combines multiple EV71 capsid proteins (VP1, VP2, VP3) into a single recombinant baculovirus construct, creating a composite antigenic material that presents multiple epitopes simultaneously. This composite approach elicits broader and stronger neutralizing antibody responses compared to single-protein vaccines.
Data Source
AI summary
An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence.